XOMA Royalty (XOMA) Competitors

XOMA Royalty (NASDAQ:XOMA) and Innoviva (NASDAQ:INVA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, institutional ownership, dividends, analyst recommendations, risk and earnings.

Do analysts prefer XOMA or INVA?

XOMA Royalty presently has a consensus target price of $69.50, suggesting a potential upside of 165.57%. Innoviva has a consensus target price of $55.00, suggesting a potential upside of 190.85%. Given Innoviva's higher possible upside, analysts plainly believe Innoviva is more favorable than XOMA Royalty.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XOMA Royalty	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Innoviva	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has better valuation and earnings, XOMA or INVA?

Innoviva has higher revenue and earnings than XOMA Royalty. XOMA Royalty is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XOMA Royalty	$28.49M	11.00	-$13.82M	-$1.15	-22.76
Innoviva	$358.71M	3.31	$23.39M	-$1.01	-18.72

Do insiders and institutionals hold more shares of XOMA or INVA?

95.9% of XOMA Royalty shares are held by institutional investors. Comparatively, 99.1% of Innoviva shares are held by institutional investors. 7.2% of XOMA Royalty shares are held by insiders. Comparatively, 2.3% of Innoviva shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Does the media favor XOMA or INVA?

In the previous week, XOMA Royalty and XOMA Royalty both had 1 articles in the media. XOMA Royalty's average media sentiment score of 0.74 beat Innoviva's score of 0.00 indicating that XOMA Royalty is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
XOMA Royalty	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Innoviva	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has more volatility and risk, XOMA or INVA?

XOMA Royalty has a beta of 0.93, suggesting that its share price is 7% less volatile than the S&P 500. Comparatively, Innoviva has a beta of 0.37, suggesting that its share price is 63% less volatile than the S&P 500.

Is XOMA or INVA more profitable?

XOMA Royalty has a net margin of -13.04% compared to Innoviva's net margin of -16.15%. Innoviva's return on equity of 15.77% beat XOMA Royalty's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
XOMA Royalty	-13.04%	-12.43%	-4.85%
Innoviva	-16.15%	15.77%	8.41%

Summary

Innoviva beats XOMA Royalty on 8 of the 13 factors compared between the two stocks.